SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”), Carlyle (NASDAQ: CG) (“Carlyle”) and SK Capital Partners, LP (“SK ...
bluebird will focus on expanding manufacturing capacity and improving the treatment experience for patients and providers David Meek, who became Chief Executive Officer of bluebird at close, said, ...
The new $5-per-share offer can be viewed as a win for bluebird investors, as the original deal's CVR term seems unattainable. (designer491/iStock/Getty Images Plus ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
All conditions of the Offer have been satisfied and the parties expect to consummate the acquisition on June 2, 2025 WASHINGTON & NEW YORK--(BUSINESS WIRE)--Carlyle (NASDAQ: CG) (“Carlyle”), SK ...
Investors in bluebird bio have agreed to a sale to Carlyle and SK Capital after weeks of refusing to tender their shares. (SOPA Images/LightRocket/Getty Images) With a better upfront offer on the ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min After a back and forth with two ...
David Meek, former CEO of Mirati Therapeutics and Ipsen, is expected to become CEO of bluebird upon closing The transaction is expected to close in the first half of 2025 At the closing of the ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Under the terms of the amended agreement bluebird stockholders can elect to receive either (x) the original offer of $3.00 per share in cash plus a contingent value right (“CVR”) of $6.84 per share in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results